Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Nov;52(11):793–803. doi: 10.1136/jcp.52.11.793

Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

R Montironi 1, R Mazzucchelli 1, J R Marshall 1, P H Bartels 1
PMCID: PMC501588  PMID: 10690166

Full text

PDF
793

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet. 1993 Nov 13;342(8881):1209–1210. doi: 10.1016/0140-6736(93)92188-y. [DOI] [PubMed] [Google Scholar]
  2. Alers J. C., Krijtenburg P. J., Vissers K. J., Bosman F. T., van der Kwast T. H., van Dekken H. Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer. 1995 Apr;12(4):241–250. doi: 10.1002/gcc.2870120402. [DOI] [PubMed] [Google Scholar]
  3. Bacus S., Chin D., Stewart J., Zelnick C., Mahvi D., Gilchrist K. Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers. Anal Quant Cytol Histol. 1997 Aug;19(4):316–328. [PubMed] [Google Scholar]
  4. Bartels P. H., Bartels H. G., Montironi R., Hamilton P. W., Thompson D. Machine vision in the detection of prostate lesions in histologic sections. Anal Quant Cytol Histol. 1998 Oct;20(5):358–364. [PubMed] [Google Scholar]
  5. Bartels P. H., Montironi R., Thompson D., Vaught L., Hamilton P. W. Statistical histometry of the basal cell/secretory cell bilayer in prostatic intraepithelial neoplasia. Anal Quant Cytol Histol. 1998 Oct;20(5):381–388. [PubMed] [Google Scholar]
  6. Bartels P. H., da Silva V. D., Montironi R., Hamilton P. W., Thompson D., Vaught L., Bartels H. G. Chromatin texture signatures in nuclei from prostate lesions. Anal Quant Cytol Histol. 1998 Oct;20(5):407–416. [PubMed] [Google Scholar]
  7. Bergerheim U. S., Kunimi K., Collins V. P., Ekman P. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer. 1991 May;3(3):215–220. doi: 10.1002/gcc.2870030308. [DOI] [PubMed] [Google Scholar]
  8. Boone C. W., Kelloff G. J. Biomarker end-points in cancer chemoprevention trials. IARC Sci Publ. 1997;(142):273–280. [PubMed] [Google Scholar]
  9. Boone C. W., Kelloff G. J. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia. J Cell Biochem Suppl. 1994;19:10–22. [PubMed] [Google Scholar]
  10. Bostwick D. G. Target populations and strategies for chemoprevention trials of prostate cancer. J Cell Biochem Suppl. 1994;19:191–196. [PubMed] [Google Scholar]
  11. Bova G. S., Carter B. S., Bussemakers M. J., Emi M., Fujiwara Y., Kyprianou N., Jacobs S. C., Robinson J. C., Epstein J. I., Walsh P. C. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 1993 Sep 1;53(17):3869–3873. [PubMed] [Google Scholar]
  12. Bozzo P. D., Vaught L. C., Alberts D. S., Thompson D., Bartels P. H. Nuclear morphometry in solar keratosis. Anal Quant Cytol Histol. 1998 Feb;20(1):21–28. [PubMed] [Google Scholar]
  13. Brooks J. D., Weinstein M., Lin X., Sun Y., Pin S. S., Bova G. S., Epstein J. I., Isaacs W. B., Nelson W. G. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):531–536. [PubMed] [Google Scholar]
  14. Burk R. F., Hill K. E. Regulation of selenoproteins. Annu Rev Nutr. 1993;13:65–81. doi: 10.1146/annurev.nu.13.070193.000433. [DOI] [PubMed] [Google Scholar]
  15. Civantos F., Soloway M. S., Pinto J. E. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol. 1996 May;14(2 Suppl 2):22–31. [PubMed] [Google Scholar]
  16. Clark L. C., Combs G. F., Jr, Turnbull B. W., Slate E. H., Chalker D. K., Chow J., Davis L. S., Glover R. A., Graham G. F., Gross E. G. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996 Dec 25;276(24):1957–1963. [PubMed] [Google Scholar]
  17. Coates R. J., Weiss N. S., Daling J. R., Morris J. S., Labbe R. F. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol. 1988 Sep;128(3):515–523. doi: 10.1093/oxfordjournals.aje.a114999. [DOI] [PubMed] [Google Scholar]
  18. Crawford E. D., DeAntoni E. P., Ross C. A. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl. 1996;25:149–155. [PubMed] [Google Scholar]
  19. Cunningham J. M., Shan A., Wick M. J., McDonnell S. K., Schaid D. J., Tester D. J., Qian J., Takahashi S., Jenkins R. B., Bostwick D. G. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 1996 Oct 1;56(19):4475–4482. [PubMed] [Google Scholar]
  20. Davidson D., Bostwick D. G., Qian J., Wollan P. C., Oesterling J. E., Rudders R. A., Siroky M., Stilmant M. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol. 1995 Oct;154(4):1295–1299. [PubMed] [Google Scholar]
  21. Ellis W. J., Isaacs J. T. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res. 1985 Dec;45(12 Pt 1):6041–6050. [PubMed] [Google Scholar]
  22. Emmert-Buck M. R., Vocke C. D., Pozzatti R. O., Duray P. H., Jennings S. B., Florence C. D., Zhuang Z., Bostwick D. G., Liotta L. A., Linehan W. M. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 1995 Jul 15;55(14):2959–2962. [PubMed] [Google Scholar]
  23. Feldman D., Skowronski R. J., Peehl D. M. Vitamin D and prostate cancer. Adv Exp Med Biol. 1995;375:53–63. doi: 10.1007/978-1-4899-0949-7_5. [DOI] [PubMed] [Google Scholar]
  24. Ferguson J., Zincke H., Ellison E., Bergstrahl E., Bostwick D. G. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology. 1994 Jul;44(1):91–95. doi: 10.1016/s0090-4295(94)80015-4. [DOI] [PubMed] [Google Scholar]
  25. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2690–2694. doi: 10.1073/pnas.90.7.2690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Giovannucci E., Rimm E. B., Colditz G. A., Stampfer M. J., Ascherio A., Chute C. G., Chute C. C., Willett W. C. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993 Oct 6;85(19):1571–1579. doi: 10.1093/jnci/85.19.1571. [DOI] [PubMed] [Google Scholar]
  27. Gormley G. J. Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. J Cell Biochem Suppl. 1992;16H:113–117. doi: 10.1002/jcb.240501226. [DOI] [PubMed] [Google Scholar]
  28. Han X., Liehr J. G., Bosland M. C. Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone. Carcinogenesis. 1995 Apr;16(4):951–954. doi: 10.1093/carcin/16.4.951. [DOI] [PubMed] [Google Scholar]
  29. Hedlund T. E., Moffatt K. A., Uskokovic M. R., Miller G. J. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331–1338. [PubMed] [Google Scholar]
  30. Ingles S. A., Ross R. K., Yu M. C., Irvine R. A., La Pera G., Haile R. W., Coetzee G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997 Jan 15;89(2):166–170. doi: 10.1093/jnci/89.2.166. [DOI] [PubMed] [Google Scholar]
  31. Joseph I. B., Vukanovic J., Isaacs J. T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 1996 Aug 1;56(15):3404–3408. [PubMed] [Google Scholar]
  32. Kadmon D. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1992;16H:122–127. doi: 10.1002/jcb.240501228. [DOI] [PubMed] [Google Scholar]
  33. Kadomatsu K., Anzano M. A., Slayter M. V., Winokur T. S., Smith J. M., Sporn M. B. Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. Cancer Res. 1993 Apr 1;53(7):1480–1483. [PubMed] [Google Scholar]
  34. Karp J. E., Chiarodo A., Brawley O., Kelloff G. J. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res. 1996 Dec 15;56(24):5547–5556. [PubMed] [Google Scholar]
  35. Kelloff G. J., Hawk E. T., Crowell J. A., Boone C. W., Nayfield S. G., Perloff M., Steele V. E., Lubet R. A. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 1996 Oct;10(10):1471–1488. [PubMed] [Google Scholar]
  36. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994 Dec 23;266(5193):2011–2015. doi: 10.1126/science.7605428. [DOI] [PubMed] [Google Scholar]
  37. Klocker H., Culig Z., Kaspar F., Hobisch A., Eberle J., Reissigl A., Bartsch G. Androgen signal transduction and prostatic carcinoma. World J Urol. 1994;12(2):99–103. doi: 10.1007/BF00184245. [DOI] [PubMed] [Google Scholar]
  38. Knekt P., Aromaa A., Maatela J., Alfthan G., Aaran R. K., Hakama M., Hakulinen T., Peto R., Teppo L. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst. 1990 May 16;82(10):864–868. doi: 10.1093/jnci/82.10.864. [DOI] [PubMed] [Google Scholar]
  39. Kokontis J., Takakura K., Hay N., Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994 Mar 15;54(6):1566–1573. [PubMed] [Google Scholar]
  40. Leav I., Ho S. M., Ofner P., Merk F. B., Kwan P. W., Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst. 1988 Sep 7;80(13):1045–1053. doi: 10.1093/jnci/80.13.1045. [DOI] [PubMed] [Google Scholar]
  41. Lieberman R., Crowell J. A., Hawk E. T., Boone C. W., Sigman C. C., Kelloff G. J. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem. 1998 Feb;44(2):420–427. [PubMed] [Google Scholar]
  42. Love R. R., Carbone P. P., Verma A. K., Gilmore D., Carey P., Tutsch K. D., Pomplun M., Wilding G. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst. 1993 May 5;85(9):732–737. doi: 10.1093/jnci/85.9.732. [DOI] [PubMed] [Google Scholar]
  43. MacGrogan D., Levy A., Bostwick D., Wagner M., Wells D., Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer. 1994 Jul;10(3):151–159. doi: 10.1002/gcc.2870100302. [DOI] [PubMed] [Google Scholar]
  44. Mariuzzi G. M., Mariuzzi L., Mombello A., Santinelli A., Valli M., Rahal D., Thompson D., Bartels P. H. Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma. Pathol Res Pract. 1996 May;192(5):428–436. doi: 10.1016/S0344-0338(96)80004-5. [DOI] [PubMed] [Google Scholar]
  45. Montironi R., Bartels P. H., Thompson D., Bartels H. G., Scarpelli M. Prostatic intraepithelial neoplasia. Quantitation of the basal cell layer with machine vision system. Pathol Res Pract. 1995 Sep;191(9):917–923. doi: 10.1016/S0344-0338(11)80977-5. [DOI] [PubMed] [Google Scholar]
  46. Montironi R., Diamanti L., Thompson D., Bartels H. G., Bartels P. H. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol. 1996;30(2):191–200. doi: 10.1159/000474169. [DOI] [PubMed] [Google Scholar]
  47. Montironi R., Magi Galluzzi C. M., Marina S., Diamanti L. Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem Suppl. 1994;19:238–245. [PubMed] [Google Scholar]
  48. Montironi R., Scarpelli M., Sisti S., Braccischi A., Gusella P., Pisani E., Alberti R., Mariuzzi G. M. Quantitative analysis of prostatic intraepithelial neoplasia on tissue sections. Anal Quant Cytol Histol. 1990 Oct;12(5):366–372. [PubMed] [Google Scholar]
  49. Montironi R., Schulman C. C. Precursors of prostatic cancer: progression, regression and chemoprevention. Eur Urol. 1996;30(2):133–137. doi: 10.1159/000474162. [DOI] [PubMed] [Google Scholar]
  50. Morton M. S., Griffiths K., Blacklock N. The preventive role of diet in prostatic disease. Br J Urol. 1996 Apr;77(4):481–493. doi: 10.1046/j.1464-410x.1996.09361.x. [DOI] [PubMed] [Google Scholar]
  51. Nelson P. S., Gleason T. P., Brawer M. K. Chemoprevention for prostatic intraepithelial neoplasia. Eur Urol. 1996;30(2):269–278. doi: 10.1159/000474180. [DOI] [PubMed] [Google Scholar]
  52. Peehl D. M., Skowronski R. J., Leung G. K., Wong S. T., Stamey T. A., Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994 Feb 1;54(3):805–810. [PubMed] [Google Scholar]
  53. Peehl D. M., Wong S. T., Stamey T. A. Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells. Prostate. 1993;23(1):69–78. doi: 10.1002/pros.2990230107. [DOI] [PubMed] [Google Scholar]
  54. Petein M., Michel P., van Velthoven R., Pasteels J. L., Brawer M. K., Davis J. R., Nagle R. B., Kiss R. Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. Am J Clin Pathol. 1991 Nov;96(5):628–634. doi: 10.1093/ajcp/96.5.628. [DOI] [PubMed] [Google Scholar]
  55. Pienta K. J., Nguyen N. M., Lehr J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993 Jan 15;53(2):224–226. [PubMed] [Google Scholar]
  56. Pollard M. The Lobund-Wistar rat model of prostate cancer. J Cell Biochem Suppl. 1992;16H:84–88. doi: 10.1002/jcb.240501220. [DOI] [PubMed] [Google Scholar]
  57. Qian J., Bostwick D. G., Takahashi S., Borell T. J., Herath J. F., Lieber M. M., Jenkins R. B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res. 1995 Nov 15;55(22):5408–5414. [PubMed] [Google Scholar]
  58. Qian J., Jenkins R. B., Bostwick D. G. Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization. Eur Urol. 1996;30(2):177–184. doi: 10.1159/000474167. [DOI] [PubMed] [Google Scholar]
  59. Rhyu M. S. Telomeres, telomerase, and immortality. J Natl Cancer Inst. 1995 Jun 21;87(12):884–894. doi: 10.1093/jnci/87.12.884. [DOI] [PubMed] [Google Scholar]
  60. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  61. Sakr W. A., Grignon D. J., Haas G. P., Heilbrun L. K., Pontes J. E., Crissman J. D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 1996;30(2):138–144. doi: 10.1159/000474163. [DOI] [PubMed] [Google Scholar]
  62. Sakr W. A., Macoska J. A., Benson P., Grignon D. J., Wolman S. R., Pontes J. E., Crissman J. D. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 1994 Jun 15;54(12):3273–3277. [PubMed] [Google Scholar]
  63. Scates D. K., Muir G. H., Venitt S., Carmichael P. L. Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? Br J Urol. 1997 Aug;80(2):263–268. doi: 10.1046/j.1464-410x.1997.00248.x. [DOI] [PubMed] [Google Scholar]
  64. Schwartz G. G., Oeler T. A., Uskoković M. R., Bahnson R. R. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res. 1994 May-Jun;14(3A):1077–1081. [PubMed] [Google Scholar]
  65. Shirai T., Yamamoto A., Iwasaki S., Tamano S., Masui T. Induction of invasive carcinomas of the seminal vesicles and coagulating glands of F344 rats by administration of N-methylnitrosourea or N-nitrosobis(2-oxopropyl)amine and followed by testosterone propionate with or without high-fat diet. Carcinogenesis. 1991 Nov;12(11):2169–2173. doi: 10.1093/carcin/12.11.2169. [DOI] [PubMed] [Google Scholar]
  66. Siegal J. A., Yu E., Brawer M. K. Topography of neovascularity in human prostate carcinoma. Cancer. 1995 May 15;75(10):2545–2551. doi: 10.1002/1097-0142(19950515)75:10<2545::aid-cncr2820751022>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  67. Slayter M. V., Anzano M. A., Kadomatsu K., Smith J. M., Sporn M. B. Histogenesis of induced prostate and seminal vesicle carcinoma in Lobund-Wistar rats: a system for histological scoring and grading. Cancer Res. 1994 Mar 15;54(6):1440–1445. [PubMed] [Google Scholar]
  68. Smith J. R., Freije D., Carpten J. D., Grönberg H., Xu J., Isaacs S. D., Brownstein M. J., Bova G. S., Guo H., Bujnovszky P. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996 Nov 22;274(5291):1371–1374. doi: 10.1126/science.274.5291.1371. [DOI] [PubMed] [Google Scholar]
  69. Takahashi S., Qian J., Brown J. A., Alcaraz A., Bostwick D. G., Lieber M. M., Jenkins R. B. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res. 1994 Jul 1;54(13):3574–3579. [PubMed] [Google Scholar]
  70. Thompson I. M., Coltman C. A., Jr, Crowley J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate. 1997 Nov 1;33(3):217–221. doi: 10.1002/(sici)1097-0045(19971101)33:3<217::aid-pros11>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  71. Weinstein M. H., Epstein J. I. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol. 1993 Jun;24(6):624–629. doi: 10.1016/0046-8177(93)90242-9. [DOI] [PubMed] [Google Scholar]
  72. Willett W. C., Polk B. F., Morris J. S., Stampfer M. J., Pressel S., Rosner B., Taylor J. O., Schneider K., Hames C. G. Prediagnostic serum selenium and risk of cancer. Lancet. 1983 Jul 16;2(8342):130–134. doi: 10.1016/s0140-6736(83)90116-2. [DOI] [PubMed] [Google Scholar]
  73. Wills M. L., Hamper U. M., Partin A. W., Epstein J. I. Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology. 1997 Mar;49(3):367–373. doi: 10.1016/S0090-4295(96)00622-X. [DOI] [PubMed] [Google Scholar]
  74. Yoshizawa K., Willett W. C., Morris S. J., Stampfer M. J., Spiegelman D., Rimm E. B., Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst. 1998 Aug 19;90(16):1219–1224. doi: 10.1093/jnci/90.16.1219. [DOI] [PubMed] [Google Scholar]
  75. Young C. Y., Murtha P. E., Andrews P. E., Lindzey J. K., Tindall D. J. Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate. 1994 Jul;25(1):39–45. doi: 10.1002/pros.2990250106. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES